NCI-H226, NCI-H358 and NIH:OVCAR3 cells were obtained from ATCC. The ovarian cancer cell lines screened for RG7787 sensitivity at Horizon Inc. were obtained from the following providers: ATCC (Caov-3, Caov-4, and OVCAR3), Public Health England’s European Collection of Authenticated Cell Cultures (59M, COV504, and OV56), Health Science Research Resources Bank (KURAMOCHI and OVSAHO), Sigma (COV664), DSMZ (EFO-21), Riken (JHOS-2) and Korean Cell Line Bank (SNU-119).
Pleural fluid containing CA-125 at 183,600 U/ml was purchased from ADVY Chemical (Mumbai, India). CellTiter-Glo® reagent was from Promega (Mannheim, Germany). 293Fectin, cell culture medium, 6-carboxy-fluorescein succinimidyl ester (CFSE), and pcDNA 3.1 vector were obtained from Thermo Fisher Scientific (Darmstadt, Germany). For surface plasmon resonance (SPR) measurements, CM5 Sensor Chips, Amine Coupling Kit, Human Antibody Capture Kit, and 10x HBS-N-buffer from GE Healthcare were used (Dornstadt, Germany). PBS 10x, Tween 20, and BSA were from Roche (Sigma-Aldrich distributor; Taufkirchen, Germany). RG7787 has been previously described26 (link) and was produced at Roche from inclusion bodies by refolding37 (link).
If not otherwise indicated, all experiments were repeated at least twice.
Free full text: Click here